Evasc Neurovascular recently announced a “landmark achievement” during the 2024 European Society of Minimally Invasive Neurological Therapy (ESMINT) congress (4–6 September, Marseille, France), reporting that more than 300 patients have been successfully treated with the company’s Eclips device.
As per a recent Evasc press release, this milestone further underscores the efficacy and safety of the “unique and revolutionary” Eclips remodelling system in treating cerebral bifurcation aneurysms—and marks a pivotal point in the company’s mission to enhance outcomes for patients with complex cerebrovascular conditions.
The 2024 ESMINT congress saw Leif Sørensen (Aarhus University Hospital, Aarhus, Denmark) detail comprehensive multisite experiences with the Eclips implant for the endovascular treatment of bifurcation aneurysms.
Sørensen’s findings—through a follow-up period of 38 months—included a 1% neurologic mortality rate, 1.8% catheter-induced stroke rate and 4.3% repeat procedure rate. Sørensen also reported an absence of post-procedural thromboembolic events, a complete occlusion rate (Raymond-Roy occlusion classification [RROC] 1) of 85%, and a satisfactory occlusion rate (RROC 1–2) of 96%, reaffirming that Eclips implants exhibit a robust safety profile and sustained efficacy, according to Evasc.
The company also claims in its recent release that these results reinforce the device’s potential within minimally invasive neurological therapy.
The release goes on to note that Evasc’s EESIS-France trial is “progressing well” and is on schedule for completion by the end of this year. The core lab-adjudicated results from the EESIS-France study—which the company anticipates will be presented next year—are expected to provide further validation of the Eclips device’s performance. This trial also builds on the positive outcomes witnessed in the initial core lab-controlled EESIS trial and the low aspect ratio score trial, “paving the way for broader clinical acceptance”.
“Looking ahead, Evasc Neurovascular is optimistic about the Eclips device’s potential to become the preferred treatment option for bifurcation aneurysms, especially with its newest version, the EBFD [Eclips bifurcation flow diverter]—a flow diverter that can be used at a bifurcation without adjuvant coiling,” the release adds. “The company’s unwavering commitment to innovation, backed by robust clinical data and continuous improvement, positions it at the forefront of minimally invasive neurological therapy.”
